Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Registrational Study To Assess The Efficacy, Safety, And Tolerability Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

NCT07770828 is registered in ClinicalTrials.gov with Ocugen as lead sponsor.

NCT NCT07770828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07770828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Registrational Study To Assess The Efficacy, Safety, And Tolerability Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
Lead sponsor
Ocugen
Phase
Phase 3
Overall status
Recruiting
Start date
August 11, 2026
Completion date
July 30, 2031
Enrollment
237 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dry age-related macular degeneration